Acute promyelocytic leukaemia (APL) in a patient with Crohn's disease and exposure to infliximab: A rare clinical presentation and review of the literature

BMJ Case Reports

Volumn , Issue , 2014, Pages

  Mohammad, Farhan ^a   Vivekanandarajah, Abhirami ^a   Haddad, Housam ^a   Shutty, Christopher M ^a   Hurford, Matthew T ^a   Dai, Qun ^a  

^a STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CD33 ANTIGEN; CYANOCOBALAMIN; ETANERCEPT; FOLIC ACID; IDARUBICIN; INFLIXIMAB; IRON; MERCAPTOPURINE; MICROSOMAL AMINOPEPTIDASE; RETINOIC ACID; SALAZOSULFAPYRIDINE; STEM CELL FACTOR RECEPTOR; STEROID;

ADULT; ARTICLE; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CANCER REGRESSION; CASE REPORT; CELL MATURATION; CHRONIC DIARRHEA; CONSOLIDATION CHEMOTHERAPY; CROHN DISEASE; CYTOGENETICS; DRUG TOLERABILITY; ERYTHROID PRECURSOR CELL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; IRON DEFICIENCY ANEMIA; IRON THERAPY; LEUKOCYTE COUNT; LEUKOPENIA; MEGAKARYOCYTE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REPEAT PROCEDURE; TREATMENT RESPONSE;

EID: 84901323293     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2013-203318     Document Type: Article

References (17)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51.
2. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003;102:43-52. (Pubitemid 36759634)
3. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999;5:119-33.
4. Biancone L, Orlando A, Kohn A, et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006;55:228 -33.
5. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty26 cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8. (Pubitemid 35453523)
6. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005;54:617-22. (Pubitemid 40559243)
7. Pedersen N, Duricova D, Elkjaer M, et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 2010;105:1480-7.
8. Anderson LA, Pfeiffer RM, Landgren O, et al. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009;100:822-8.
9. Mir Madjlessi SH, Farmer RG, Weick JK. In flammatory bowel disease and leukemia. A report of seven cases of leukemia in ulcerative colitis and Crohn's disease and review of the literature. Dig Dis Sci 1986;31:1025-31. (Pubitemid 16025637)
10. Alcain G, Andrade RJ, Queipo de Llano MP, et al. Acute leukemia after infliximab therapy. Am J Gastroenterol 2003;98:2577.
11. Kemta Lekpa F, Zahra K, Pautas C, et al. Acute myeloid leukemia after infliximab: a case report. Clin Exp Rheumatol 2009;27:999-1000.
12. Bakland G, Nossent H. Acute myelogenous leukaemia following etanercept therapy. Rheumatology (Oxford) 2003;42:900 -1.
13. Bachmeyer C, Thioliere B, Khosrotehrani K, et al. Acute myelogenous leukemia in a patient receiving etanercept for psoriasis. J Am Acad Dermatol 2007;56:169-70. (Pubitemid 44969294)
14. Nair B, Raval G, Mehta P, TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol 2007;82:1022-4. (Pubitemid 350004395)
15. Saba NS, Kosseifi SG, Charaf EA, et al. Adalimumab-induced acute myelogenic leukemia. South Med J 2008;101:1261-2.
16. Hong Ki Min JHL, Lee HM, Koh E, et al. A case of acute myeloid leukemia after adalimumab treatment in psoriatic arthritis. J Rheum Dis 2012;19:91-4.
17. Yano Y, Matsui T, Hirai F, et al. Cancer risk in Japanese Crohn's disease patients: investigation of the standardized incidence ratio. J Gastroenterol Hepatol 2013;28:1300-5.